Related Experiment Videos
[Growth hormone receptor antagonists: potential indications].
A F Muller1, J A Janssen, W W de Herder
1Erasmus Universitair Medisch Centrum, afd. Inwendige Geneeskunde, Dr. Molewaterplein 40, 3015 GD Rotterdam. muller@inw3.azr.nl
Nederlands Tijdschrift Voor Geneeskunde
|February 28, 2001
Summary
Pegvisomant, a growth hormone receptor antagonist, effectively treats acromegaly. It shows potential for managing diabetic complications and inhibiting tumor growth, with human studies forthcoming.
Area of Science:
- Endocrinology
- Oncology
- Metabolic Diseases
Background:
- Pegvisomant is a mutated human growth hormone (hGH) analog that antagonizes the hGH receptor.
- Acromegaly is characterized by excessive hGH production, leading to various health complications.
- Growth hormone (GH) and its mediator insulin-like growth factor-I (IGF-I) play roles in diabetes complications and tumor growth.
Purpose of the Study:
- To evaluate pegvisomant's efficacy in treating acromegaly.
- To explore the potential benefits of GH receptor antagonism in managing diabetes mellitus and its complications.
- To investigate pegvisomant's anti-tumorigenic effects in preclinical cancer models.
Main Methods:
- Short-term clinical study in acromegaly patients.
- Theoretical assessment of GH antagonism in diabetes.
- Preclinical animal studies using human colon and breast cancer models.
Main Results:
- Pegvisomant demonstrated short-term efficacy in treating acromegaly.
- Animal models suggest pegvisomant may mitigate diabetic retinopathy and nephropathy.
- Pegvisomant significantly reduced tumor growth in animal models of colon and breast cancer.
Conclusions:
- Pegvisomant is an effective treatment for acromegaly.
- Further clinical investigation is warranted for pegvisomant's role in diabetes mellitus and cancer treatment.
- Pegvisomant holds promise for addressing GH-related pathologies beyond acromegaly.